Helicobacter pylori and non-malignant diseases

Area of Science:

• Gastroenterology
• Microbiology
• Internal Medicine

Background:

• Helicobacter pylori (H. pylori) infection is linked to various non-malignant upper gastrointestinal diseases.
• Recent literature (March 2004-April 2005) provides updated insights into this association.
• H. pylori eradication is a key therapeutic consideration for related conditions.

Purpose of the Study:

• To review recent literature on the association between H. pylori and non-malignant upper GI diseases.
• To evaluate the efficacy of H. pylori eradication in different clinical contexts.
• To assess the implications of H. pylori eradication on NSAID use and GORD.

Main Methods:

• Literature review of studies published between March 2004 and April 2005.
• Analysis of data concerning H. pylori eradication outcomes in peptic ulcer disease, non-ulcer dyspepsia, and NSAID users.
• Examination of the relationship between H. pylori and gastro-esophageal reflux disease (GORD).

Main Results:

• H. pylori eradication shows the highest benefit in curing peptic ulcer disease.
• The benefit is smaller for non-ulcer dyspepsia, though a test-and-treat strategy is cost-effective for uninvestigated dyspepsia.
• Eradication is valuable for chronic NSAID users but does not fully prevent NSAID-related ulcers. A negative association with GORD exists, particularly in Asia, needing further clarification.

Conclusions:

• H. pylori eradication is indicated for associated non-malignant diseases, with variable efficacy.
• The 'test and treat' strategy for H. pylori in dyspepsia is generally cost-effective.
• Further research is needed to clarify the H. pylori-GORD relationship and the role of eradication in NSAID users.